Oncotarget

Research Papers:

Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer

Soma Samanta, Shuzo Tamura, Louis Dubeau, Paulette Mhawech-Fauceglia, Yohei Miyagi, Hisamori Kato, Rich Lieberman, Ronald J. Buckanovich, Yvonne G. Lin and Nouri Neamati _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:103543-103556. https://doi.org/10.18632/oncotarget.21569

Metrics: PDF 909 views  |   HTML 1873 views  |   ?  


Abstract

Soma Samanta1, Shuzo Tamura1, Louis Dubeau2, Paulette Mhawech-Fauceglia2, Yohei Miyagi3, Hisamori Kato3, Rich Lieberman4, Ronald J. Buckanovich4,5, Yvonne G. Lin2,6 and Nouri Neamati1

1Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan

2USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

3Kanagawa Cancer Center Research Institute, Yokohama, Japan

4Department of Internal Medicine, Division of Hematology Oncology, Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan

5Current/Present affiliation: Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA

6Current/Present affiliation: Genentech-Roche, South San Francisco, California, USA

Correspondence to:

Nouri Neamati, email: neamati@umich.edu

Keywords: tissue microarray (TMA), ovarian cancer, PDI family proteins, clinical outcome, patient survival

Received: June 04, 2017     Accepted: September 07, 2017     Published: October 06, 2017

ABSTRACT

Objective: Protein disulfide isomerase (PDI) is an oxidoreductase that is overexpressed in several cancers. PDI family members (PDIs) play a role in various diseases including cancer. Select PDIs were reported as useful markers in other cancers but their expression in ovarian cancer has not been thoroughly assessed. We sought to evaluate the expression of PDI, PDIA6, PDIR, ERp57, ERp72 and AGR3 in ovarian cancer patient samples and examine their prognostic significance.

Methods: TMA samples from 415 tissues collected from three cancer centers (UM, USC, and KCCRI) were used to assess the expression levels of PDI family proteins using IHC.

Results: We observed significant increases in PDI (p = 9.16E-36), PDIA6 (p = 5.51E-33), PDIR (p = 1.81E-12), ERp57 (p = 9.13E-07), ERp72 (p = 3.65E-22), and AGR3 (p = 4.56E-24) expression in ovarian cancers compared to normal tissues. Expression of PDI family members also increases during disease progression (p <0.001). All PDI family members are overexpressed in serous ovarian cancer (p<0.001). However, PDI, PDIA6, PDIR, ERp72 and AGR3 are more significantly overexpressed (p<0.001) than ERp57 (p<0.05) in clear cell ovarian carcinoma. Importantly, overexpression of PDI family members is associated with poor survival in ovarian cancer (p = 0.045 for PDI, p = 0.047 for PDIR, p = 0.037 for ERp57, p = 0.046 for ERp72, p = 0.040 for AGR3) with the exception of PDIA6 (p = 0.381).

Conclusions: Our findings demonstrate that select PDI family members (PDI, PDIR, ERp72, ERp57 and AGR3) are potential prognostic markers for ovarian cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21569